CM
LEGN icon

Crestline Management’s Legend Biotech LEGN Stock Holding History

Crestline Management’s Portfolio LEGN Stock Details LEGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-15,034
Closed -$733K – 814
2024
Q3 		$733K Buy
+15,034
New +$801K 0.04% 312
2020
Q3 		– Sell
-25,000
Closed -$1.06M – 153
2020
Q2 		$1.06M Buy
+25,000
New +$977K 0.2% 47

Other funds holding LEGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Crestline Management's LEGN Position: Q4 2024 in Review

Crestline Management sold out of Legend Biotech (LEGN) in Q4 2024, closing a stake of 15,034 shares — an estimated $733K sold.

Crestline Management first reported a position in LEGN in Q2 2020 and held it in 2 quarters. The position peaked at $1.06M in Q2 2020. 211 funds tracked by Wall St. Rank hold LEGN as of Q4 2024.

  • Crestline Management reported no remaining Legend Biotech position as of Q4 2024 after selling out during the quarter.
  • Crestline Management sold 15,034 Legend Biotech shares in Q4 2024, an estimated $733K.
  • Crestline Management first reported a position in Legend Biotech in Q2 2020 and held it in 2 quarters.
  • Crestline Management's Legend Biotech position peaked at $1.06M in Q2 2020.
  • 211 funds tracked by Wall St. Rank held Legend Biotech as of Q4 2024.

Based on Crestline Management's 13F filing for Q4 2024, filed 14 Feb 2025.